* Market Opportunity: Breast Cancer > $20B, 20m Mammograms/year in US, 15% result in "call backs"
​* Technology: Non-invasive saliva testing
* Management Team: Life Sciences Veterans. Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics

---

NEPHROSANT has a unique non-invasive urine diagnostic, with a proprietary urine life extender preservative, that gives accurate and actionable clinical results quickly, with a compact device and reader designed for point of care testing. Kidney injury is treatable, but usually asymptomatic until later stages and not reversible once it progresses to Stage 3. We invested in this company because the CEO is incredibly impressive and the test has the highest sensitivity/specificity (90’s), far exceeding CareDX & Natera, the market leaders. The company has potentially foundational patents in the kidney transplant space. The founder is a nationally recognized expert with her own lab at UCSF and can monetize under existing codes. She has also patented both her urine life extender and transplant rejection IP. In July 2019, the White House announced its focus on kidney disease. In August, Natera reached out to the company to start a dialogue. Stellar team and solid investment. (They also secured CLIA lab space with a strategy to accelerate the approval process.)